Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) is one of 896 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Ocular Therapeutix to related businesses based on the strength of its institutional ownership, valuation, earnings, risk, profitability, dividends and analyst recommendations.
Risk and Volatility
Ocular Therapeutix has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500. Comparatively, Ocular Therapeutix’s competitors have a beta of -3.71, suggesting that their average share price is 471% less volatile than the S&P 500.
Profitability
This table compares Ocular Therapeutix and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ocular Therapeutix | -579.10% | -59.89% | -45.99% |
| Ocular Therapeutix Competitors | -2,380.39% | -218.78% | -15.59% |
Valuation & Earnings
This table compares Ocular Therapeutix and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Ocular Therapeutix | $51.95 million | -$265.94 million | -4.60 |
| Ocular Therapeutix Competitors | $5.43 billion | $3.22 billion | 553.82 |
Ocular Therapeutix’s competitors have higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a breakdown of recent ratings and target prices for Ocular Therapeutix and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ocular Therapeutix | 1 | 1 | 8 | 1 | 2.82 |
| Ocular Therapeutix Competitors | 7798 | 13891 | 25786 | 1038 | 2.41 |
Ocular Therapeutix presently has a consensus price target of $23.33, suggesting a potential upside of 256.89%. As a group, “Pharmaceuticals” companies have a potential upside of 24.77%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Ocular Therapeutix is more favorable than its competitors.
Institutional & Insider Ownership
59.2% of Ocular Therapeutix shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.1% of Ocular Therapeutix shares are owned by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
Ocular Therapeutix beats its competitors on 8 of the 13 factors compared.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.
